Abstract
The damage of axons and neurons in multiple sclerosis (MS) is well recognised and correlates with neurological disability. The reasons leading to axonal and neuronal injury are diverse and possibly change from an inflammatory mediated mechanism to a neurodegenerative mechanism over the course of the disease. Acute axonal injury is associated with inflammation in the CNS and thus immunomodulatory treatments may also protect neurons from further damage. However, more effective immune treatments also bear the risk for severe side effects. Thus, neuroprotection will become more important to be combined with safe immunomodulation. Although several targets for neuroprotection have been identified experimentally, the translation into clinical treatments proves very difficult. Only few and small trials have investigated substances that may be neuroprotective, however, none had proven to have a substantial effect in MS patients. Clinical trials of remyelination, considered as a natural way of neuroprotection, were likewise not able to achieve clinical benefit. Thus, the development of a neuroprtective treatment in MS will be a major challenge in the decades to come.
Keywords: Neurodegeneration, axonal injury, neuroprotection, clinical trial, remyelination, repair, axons, neurons, multiple sclerosis (MS), CNS.
Current Pharmaceutical Design
Title:Neurodegeneration and Neuroprotection in Multiple Sclerosis
Volume: 18 Issue: 29
Author(s): Martin Stangel
Affiliation:
Keywords: Neurodegeneration, axonal injury, neuroprotection, clinical trial, remyelination, repair, axons, neurons, multiple sclerosis (MS), CNS.
Abstract: The damage of axons and neurons in multiple sclerosis (MS) is well recognised and correlates with neurological disability. The reasons leading to axonal and neuronal injury are diverse and possibly change from an inflammatory mediated mechanism to a neurodegenerative mechanism over the course of the disease. Acute axonal injury is associated with inflammation in the CNS and thus immunomodulatory treatments may also protect neurons from further damage. However, more effective immune treatments also bear the risk for severe side effects. Thus, neuroprotection will become more important to be combined with safe immunomodulation. Although several targets for neuroprotection have been identified experimentally, the translation into clinical treatments proves very difficult. Only few and small trials have investigated substances that may be neuroprotective, however, none had proven to have a substantial effect in MS patients. Clinical trials of remyelination, considered as a natural way of neuroprotection, were likewise not able to achieve clinical benefit. Thus, the development of a neuroprtective treatment in MS will be a major challenge in the decades to come.
Export Options
About this article
Cite this article as:
Stangel Martin, Neurodegeneration and Neuroprotection in Multiple Sclerosis, Current Pharmaceutical Design 2012; 18 (29) . https://dx.doi.org/10.2174/138161212802502189
DOI https://dx.doi.org/10.2174/138161212802502189 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index to Volume 3
Current Drug Targets - CNS & Neurological Disorders Finding the Smoking Gun: Protein Tyrosine Phosphatases as Tools and Targets of Unicellular Microorganisms and Viruses
Current Medicinal Chemistry Neurophysiological Alterations in the Prepsychotic Phases
Current Pharmaceutical Design Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry Organotypic Cultures as Tools for Testing Neuroactive Drugs – Link Between In-Vitro and In-Vivo Experiments
Current Medicinal Chemistry Connexins as Precocious Markers and Molecular Targets for Chemical and Pharmacological Agents in Carcinogenesis
Current Medicinal Chemistry Immunogenic Issues Concerning Recombinant Adeno-Associated Virus Vectors for Gene Therapy
Current Gene Therapy Effects of Obesity on Vascular Potassium Channels
Current Vascular Pharmacology Tau Silencing by siRNA in the P301S Mouse Model of Tauopathy
Current Gene Therapy (Section B: Integrated Function of Drug Transporters In Vivo) Drug Transport at the Blood-Brain Barrier and the Choroid Plexus
Current Drug Metabolism HCN Channels Modulators: The Need for Selectivity
Current Topics in Medicinal Chemistry Self-Regulatory Control and Habit Learning in the Development of Eating Disorders
Current Psychiatry Reviews Dexmedetomidine Use in General Anaesthesia
Current Drug Targets Natural Plants with Antiepileptic Activity-The Present and Future Perspectives
The Natural Products Journal NADPH Oxidase and Neurodegeneration
Current Neuropharmacology Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research Editorial [ Hot topic:Psychogenomics and Psychiatric Practice, a New Paradigm (Guest Editor: Tih-Shih Lee)]
Current Psychiatry Reviews Recent Advances in Epilepsy
Current Neuropharmacology NPY Signalling Pathway in Bone Homeostasis: Y1 Receptor as a Potential Drug Target
Current Drug Targets